OptiMedica to feature Catalys Precision Laser System at Ophthalmology annual meeting

Global ophthalmic device company OptiMedica Corp. has announced that its Catalys Precision Laser System will be featured as part of four clinical presentations at the American Academy of Ophthalmology annual meeting in Chicago on October 16, 17 and 18. The company's Catalys system, which combines a femtosecond laser, integrated Optical Coherence Tomography (OCT) imaging and OptiMedica's breakthrough pattern scanning technology, was designed to dramatically improve the cataract procedure by replacing its inconsistent, manual steps. Technological hallmarks of the Catalys system include an innovative Liquid Optics™ Interface that optimizes the optical path to the patient's eye, and a proprietary Integral Guidance™ system that ensures the femtosecond laser pulses are delivered precisely to the intended location. AAO presenters will explore the clinical results achieved through the use of these and other Catalys features as well as the system's potential to transform the future of cataract surgery.

“From OptiMedica's point of view, the future of cataract surgery is all about precision, and the Catalys Precision Laser System is designed to provide physicians with the ability to deliver unprecedented precision to benefit their patients”

Presentation details are as follows.

  • "Integrated OCT for Incision Placement in Femtosecond Laser Cataract Surgery"

Presented by Jonathan H. Talamo, M.D., Harvard Medical School and Talamo Laser Eye Consultants, on Friday, Oct. 15 at 9:34 a.m. in North Hall B1

  • "Integrated OCT in Femtosecond Laser-assisted Cataract Surgery"

Presented by Julian D. Stevens, M.D., Moorfields Eye Hospital, London, on Sunday, Oct. 17 at 10:42 a.m. in Room S102

  • "Accuracy and Predictability of the OptiMedica Femtosecond Laser Capsulotomy"

Presented by Stephen S. Lane, M.D., University of Minnesota and Associated Eye Care, on Sunday, Oct. 17 at 11:06 a.m. in Room S102

  • "Precise Femtosecond Laser-based Anterior Capsulotomies" (poster presentation)

Presented by John A. Vukich, M.D., University of Wisconsin, Madison, on Monday, Oct. 18 at 12:30 p.m. in Hall A

Drs. Talamo, Stevens, Lane and Vukich are members of OptiMedica's 12-person Cataract Advisory Board, a group of esteemed cataract experts from around the world who have worked closely with the company during every step of the Catalys Precision Laser System's development. Together, the board members have treated hundreds of eyes in pre-clinical laboratory studies, and many - including the AAO presenters - have participated in institutional review board (IRB) approved clinical studies.

"From OptiMedica's point of view, the future of cataract surgery is all about precision, and the Catalys Precision Laser System is designed to provide physicians with the ability to deliver unprecedented precision to benefit their patients," said Mark J. Forchette, OptiMedica president and chief executive officer. "The clinical results achieved to date with Catalys are extremely encouraging, as they show a truly remarkable improvement in precision and control over the manual cataract surgical technique. The data validates OptiMedica's technology, and positions us well to serve patients in this very exciting market."

The Catalys Precision Laser System is not for sale in the United States.

OptiMedica expects to launch Catalys worldwide in 2011.

Source:

OptiMedica Corp

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-READI consortium launches groundbreaking diabetes data study